These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32390401)

  • 1. The Role of Resolvin D1 in the Differential Diagnosis of the Cholangiocarcinoma and Benign Biliary Diseases.
    Gül-Utku Ö; Karatay E; Ergül B; Kisa Ü; Erdin Z; Oğuz D
    Clin Lab; 2020 May; 66(5):. PubMed ID: 32390401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma.
    Han HS; Kim MJ; Han JH; Yun J; Kim HK; Yang Y; Kim KB; Park SM
    Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):41-50. PubMed ID: 31784323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
    Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
    BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma.
    Chen J; Liang J; Xu B; Liang J; Ma M; Wang Z; Zeng G; Xu Q; Liang L; Lai J; Huang L
    J Gastrointest Cancer; 2024 Jun; 55(2):800-808. PubMed ID: 38280173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP.
    Park MS; Kim TK; Kim KW; Park SW; Lee JK; Kim JS; Lee JH; Kim KA; Kim AY; Kim PN; Lee MG; Ha HK
    Radiology; 2004 Oct; 233(1):234-40. PubMed ID: 15333766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.
    Wasenang W; Chaiyarit P; Proungvitaya S; Limpaiboon T
    Clin Epigenetics; 2019 Mar; 11(1):39. PubMed ID: 30832707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cathepsin B to cystatin C ratio as a potential marker for the diagnosis of cholangiocarcinoma.
    Monsouvanh A; Proungvitaya T; Limpaiboon T; Wongkham C; Wongkham S; Luvira V; Proungvitaya S
    Asian Pac J Cancer Prev; 2014; 15(21):9511-5. PubMed ID: 25422248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls.
    Zhang X; Yang Z; Shi Z; Zhu Z; Li C; Du Z; Zhang Y; Wang Z; Jiao Z; Tian X; Zhang J; Zhai W; Kan Q
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105775. PubMed ID: 33130021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma.
    Tummanatsakun D; Proungvitaya T; Roytrakul S; Limpaiboon T; Wongkham S; Wongkham C; Silsirivanit A; Somintara O; Sangkhamanon S; Proungvitaya S
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31454981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total serum bile acid as a potential marker for the diagnosis of cholangiocarcinoma without jaundice.
    Sombattheera S; Proungvitaya T; Limpaiboon T; Wongkham S; Wongkham C; Luvira V; Proungvitaya S
    Asian Pac J Cancer Prev; 2015; 16(4):1367-70. PubMed ID: 25743800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic Features of Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis.
    Ishii Y; Sasaki T; Serikawa M; Kobayashi K; Kamigaki M; Minami T; Okazaki A; Yukutake M; Ishigaki T; Kosaka K; Mouri T; Yoshimi S; Chayama K
    Hepatogastroenterology; 2014 May; 61(131):567-73. PubMed ID: 26176037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma.
    Tang Z; Yang Y; Wang X; Meng W; Li X
    BMJ Open; 2019 Jan; 9(1):e021693. PubMed ID: 30700476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
    Chen WM; Wei KL; Chen YS; Chang PJ; Tung SY; Chang TS; Huang HC; Shen CH; Hsieh YY; Wu CS
    World J Surg Oncol; 2016 May; 14():140. PubMed ID: 27142076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.
    Kuzu UB; Ödemiş B; Suna N; Yıldız H; Parlak E; Dişibeyaz S; Torun S; Akpınar MY; Coşkun O; Turhan N; Yüksel M; Kayaçetin E
    J Gastrointest Cancer; 2016 Mar; 47(1):8-14. PubMed ID: 26537791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study.
    Navaneethan U; Parsi MA; Lourdusamy V; Bhatt A; Gutierrez NG; Grove D; Sanaka MR; Hammel JP; Stevens T; Vargo JJ; Dweik RA
    Gastrointest Endosc; 2015 Apr; 81(4):943-9.e1. PubMed ID: 25500329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.